PropertyValue
?:abstract
  • The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics.
is ?:annotates of
?:creator
?:journal
  • Trends_Immunol
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
?:type
?:who_covidence_id
  • #844007
?:year
  • 2020

Metadata

Anon_0  
expand all